Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Atif Zaheer

Diagnostic Radiology Baltimore, MD Medical Doctor

NPI 1891825352 CMS profile 787363

600 N Wolfe St, Baltimore, MD 21287

Open in the dashboard

General payments

$114,547

74 records reported · program years 2019–2025

Research payments

$39,564

Paid to them · 7 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,190 paid to institutions, not to them · program year 2023

Through program year 2025, Atif Zaheer of Baltimore, MD is reported in the CMS Open Payments database as having received $114,547 across 74 general payments and $39,564 in research payments paid to them. Separately, studies naming them as principal investigator received $1,190 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Diagnostic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $44,291 25
2024 General $26,670 15
2023 General $11,530 10
2022 General $24,960 12
2021 General $2,210 4
2020 General $3,304 5
2020 Research $33,475 6
2019 General $1,582 3
2019 Research $6,089 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Atif Zaheer
  • Diagnostic Radiology median
  • Middle half of Diagnostic Radiology
  • National median

In program year 2025, general payments to Atif Zaheer were reported at $44,291. Among 8,325 Diagnostic Radiology profiles paid that year, the median was $112 and the middle half received between $32 and $349.

Show as a table
Year Atif Zaheer Diagnostic Radiology median Middle half National median
2019 $1,582 $108 $29–$318 $163
2020 $3,304 $65 $21–$252 $114
2021 $2,210 $92 $24–$292 $132
2022 $24,960 $104 $29–$294 $149
2023 $11,530 $110 $29–$337 $160
2024 $26,670 $113 $30–$356 $164
2025 $44,291 $112 $32–$349 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $43,095 28 payments
  2. Boehringer Ingelheim RCV GmbH & Co KG $38,700 26 payments
  3. AstraZeneca UK Limited $23,245 5 payments
  4. Merck Sharp & Dohme Corporation $4,886 8 payments
  5. Guerbet LLC $3,503 5 payments
  6. Amgen Inc. $1,118 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $112,926 69 payments
  2. Travel and Lodging $1,194 2 payments
  3. Food and Beverage $427 3 payments
Products named General payments · program years 2019–2025
  1. KEYTRUDA $4,886 8 payments
  2. Elucirem $3,503 5 payments
  3. UPLIZNA $1,118 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $39,564 7 payments

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$165,064

Of which drugs: $1,707

Medicare patients

1,308

Average age 71

Services billed

15,621

672 women, 636 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Diabetes 42%
Chronic kidney disease 42%
Ischemic heart disease 41%
Heart failure 31%
Cancer 31%
Depression 31%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 101 12,610 $1,314
Injection, gadobutrol, 0.1 ml A9585 Office 136 1,142 $278

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

81 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Diagnostic Radiology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record